PIK3CA CDx Mutation Analysis

Informing a new biomarker-driven strategy for HR+/HER2- advanced breast cancer

 For questions, please contact our PIK3CA Client Services team at 866.776.5907, option 3.

NeoGenomics Laboratories is pleased to provide FDA-approved PIK3CA Mutation CDx – Tissue as part of our collaboration with QIAGEN to offer patients Day-One access to companion diagnostics for newly-approved drugs.

Testing identifies patients who may be candidates for PIQRAY® (alpelisib), an alpha-specific PI3K inhibitor. Novartis Pharmaceuticals is providing a testing access program to eligible patients exclusively when providers order the test via NeoGenomics.

Testing is appropriate for male and post-menopausal female breast cancer patients with advanced hormone receptor-positive and HER2-negative disease who have progressed following endocrine therapy and whose tumors have a mutation in the PIK3CA gene. Primary or metastatic breast tumor specimens are acceptable.

Please review our linked Resources for full details.  Completion of the PIK3CA Mutation CDx Test Request Form is required for testing. We are looking forward to working with you in this important advance for breast cancer patients, and we welcome your questions or comments.

FAQ for Health Care Professionals

PIK3CA Testing for Advanced or Metastatic HR+/HER2- Breast Cancer with PIK3CA Mutation CDx​​​​​​​ at NeoGenomics Laboratories

Patients, please consult your medical care team to discuss whether you are a candidate for testing.

Mutations in the PIK3CA gene can act as cancer drivers and are found in ~40% of hormone receptor-positive (HR+) breast cancer cases.  They are the most common mutations in HR+ breast cancer and have been associated with a poor prognosis.  

Until 2019, there was no targeted therapy available for patients with advanced or metastatic HR+/HER2- breast cancer. PIQRAY® (alpelisib) is the first and only FDA-approved targeted therapy for patients with HR+/HER2- advanced or metastatic breast cancer who have progressed on endocrine therapy and whose tumors have a PIK3CA mutation. Only patients with a PIK3CA mutation are eligible for biomarker-driven therapy with alpelisib.

Yes, QIAGEN’s therascreen® PIK3CA RGQ PCR is the FDA-approved companion diagnostic test. NeoGenomics provides this test under the name PIK3CA Mutation CDx and it is available through an exclusive Companion Diagnostic Testing Program.

The Companion Diagnostic Testing Program is offered exclusively through NeoGenomics and is designed to ensure access to testing for patients eligible for alpelisib. Enrolled patients may receive one PIK3CA Mutation CDx by tissue and/or plasma (blood) test at no cost. Repeat tests for monitoring purposes are not accepted in this program. The Companion Diagnostic Testing Program is sponsored by Novartis Pharmaceuticals Corporation.

PIK3CA Mutation CDx – Plasma testing is appropriate when no primary or metastatic breast tumor tissue is available, or the only available tissue is decalcified and therefore unsuitable for molecular testing. Tissue is the recommended specimen type in all other cases.

Clients who require plasma testing for patients with available tissue specimens may order plasma testing concurrently with tissue testing, or plasma testing followed by tissue testing if the plasma result is negative. The Companion Diagnostic Testing Program will cover testing for one such plasma and tissue specimen pair.

The ordering health care provider must complete and sign the appropriate PIK3CA Mutation CDx Test Request Form (for either Tissue or Plasma) and submit it to NeoGenomics, or complete the information and attestation in NeoGenomics’ online ordering system. Completion of this form is required and submission also enrolls the patient in the Companion Diagnostic Testing Program.

The Test Request Form for Tissue is available here. If tests in addition to PIK3CA Mutation CDx are required on the submitted tissue specimen, please also complete a separate standard, printed NeoGenomics test requisition or create a new accession in online ordering.

The Test request Form for Plasma is available directly from Client Services at 866-776-5907, option 3, after verbal review of specimen processing requirements with our client.

NeoGenomics offers PIK3CA testing on formalin-fixed paraffin-embedded (FFPE) tumor resection or biopsy samples. Breast tumor tissue (either primary or metastatic) is required; non-breast tumors are not accepted for this test. The paraffin block is preferred. Alternatively, send 1 H&E slide plus 6-12 unstained slides for core needle biopsy (or 5-10 slides for resection) cut at 5 microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives or send decalcified specimens.

Requirements for collection, processing, and shipping plasma samples are very precise to maximize detection of circulating tumor DNA (ctDNA) in the patient’s plasma. NeoGenomics will provide a custom shipping container, collection tubes, and detailed instructions after telephone review with the client and prequalification of their account. Requirements include:

  • Processing of blood specimens within 4 hours of collection
  • High-speed centrifuge and ability to transfer plasma to new tubes
  • Low-temperature freezer (-70◦C to -90◦C)
  • Access to dry ice for shipment to NeoGenomics

Please call Client services at 866-776-5907, option 3, to prequalify before scheduling your patient’s blood draw.

The test is intended to identify PIK3CA mutation in HR+/HER2- male or post-menopausal female breast cancer patients with advanced or metastatic disease that progressed on or after endocrine therapy. Testing is appropriate when patients present with metastases. Tissue testing is preferred over plasma testing.

Overall, there is a chance of approximately 80-90% that a plasma sample result will be negative. About 60% of results are true negatives as the PIK3CA mutation frequency in tissue is approximately 40%. Plasma specimens tested in the SOLAR-1 study showed correlation with mutation-positive paired tumor specimens in approximately 55% of cases. Other studies support specimen handling and low or absent tumor DNA shedding as significant contributors to discrepancies between positive tissue and negative plasma status.

The low expected positive rate in plasma reinforces the importance of testing tissue whenever tissue is available.

Participation in the Companion Diagnostic Testing Program is available to patients whose tumors are IHC positive for either or both estrogen receptor (ER) and progesterone receptor (PgR or PR) AND negative for HER2 by IHC, ISH, or FISH.

PIK3CA Mutation CDx runs on the QIAGEN RotorGene Q MDx platform using the therascreen® PIK3CA RGQ PCR Kit. This is a real-time qualitative PCR assay for the detection of 11 mutations in the PIK3CA gene using genomic DNA extracted from FFPE breast tumor tissue or DNA extracted from cell-free peripheral blood plasma. Mutations detected are in exon 7 (C420R), exon 9 (E542K, E545A, E545D [c.1635G>T only], E545G, E545K, Q546E, Q546R), and exon 20 (H1047L, H1047R, H1047Y).

Results are typically ready in 7 days and will be sent to the ordering physician’s office or laboratory by their preferred method of delivery. Please add at least 6 days if NeoGenomics is retrieving tissue from another location.

No patient, health care program, or beneficiary shall be billed for this mutation test. If you should receive a bill, please contact the NeoGenomics Billing Department at 866-776-5907, option 2.

If you have questions about our testing process, please contact NeoGenomics Client Services at 866.776.5907 or client.services@neogenomics.com.

Further information about PIQRAY and PIK3CA is available at www.PIQRAY.com and www.PIK3CA.com.


  • therascreen® PIK3CA RGQ PCR [package insert]. Hilden, Germany: QIAGEN; document ID coming soon
  • PIQRAY® (alpelisib) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; May 2019. 
  • Andre F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.
  • LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803-3815.
  • Lee JJX, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2015;12(4):342-354.
  • Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7-24.
  • Sabine VS, Crozier C, Brookes CL, et al. Mutational analysis of PI3K/AKT signaling pathway in Tamoxifen Exemestane Adjuvant Multinational pathology study. J Clin Oncol. 2014;32(27):2951-2958.
  • Aleskandarany MA, Rakha EA, Ahmed MA, et al. PIK3CA expression in invasive breast cancer: a biomarker of poor prognosis. Breast Cancer Res Treat. 2010;122(1):45-53.
  • Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.
  • Lippi G, Chance JJ, Church S, et al. Preanalytical quality improvement: from dream to reality. Clin Chem Lab Med. 2011;49(7):1113-1126.